Korean J Ophthalmol.  2016 Oct;30(5):394-395. 10.3341/kjo.2016.30.5.394.

Systemic Minocycline Treatment of Methicillin-resistant Staphylococcus aureus in Giant Fornix Syndrome

• Lee KW
• Jung JW

• KMID: 2353835
• DOI: http://doi.org/10.3341/kjo.2016.30.5.394

Abstract

No abstract available.

MeSH Terms

Methicillin Resistance*
Methicillin-Resistant Staphylococcus aureus*
Minocycline*
Minocycline

Figure

• 

  Fig. 1 On examination, the patient's left eye presented a deep forniceal space and erythema and telangiectasis on the eyelid (A,B) with coagulum (arrow). Staining with fluorescein (C) showed a persistent epithelium defect. External photo of the patient's eye (D) showed slight blepharoptosis and swelling on the left eye. After 2 weeks of systemic minocycline treatment, the fornix (E) and corneal surface (F) were normal. The eyelid and fornix had normal clearance without discharge and the corneal surface was improved. Informed consent was received from the patient.

Reference

1. Rose GE. The giant fornix syndrome: an unrecognized cause of chronic, relapsing, grossly purulent conjunctivitis. Ophthalmology. 2004; 111:1539–1545.

2. Turaka K, Penne RB, Rapuano CJ, et al. Giant fornix syndrome: a case series. Ophthal Plast Reconstr Surg. 2012; 28:4–6.

3. Taylor JB, Fintelmann RE, Jeng BH. Subconjunctival injections and povidone-iodine washings for the treatment of giant fornix syndrome. Cornea. 2011; 30:479–480.

4. Lee H, Min K, Kim EK, Kim TI. Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction. Am J Ophthalmol. 2012; 154:949–957.e1.

5. Ta CN, He L, Mino de. In vitro antibiotic susceptibility of preoperative normal conjunctival bacteria. Eye (Lond). 2009; 23:559–560.